Evidence map›Paper›PMID 30534071›Full record

ReviewFrontiers in pharmacology2018

Challenges and Opportunities of Nanotechnology as Delivery Platform for Tocotrienols in Cancer Therapy.

Geetha Maniam, Chun-Wai Mai, Mohd Zulkefeli, Christine Dufès, Doryn Meam-Yee Tan, Ju-Yen Fu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Vitamin E in the management of pancreatic cancer: A scoping review.World journal of gastrointestinal oncology · 2023
    Article
  10. Review
  11. Review
  12. Review
  13. The anti-tumor and renoprotection study of E-[c(RGDfK)Journal of nanobiotechnology · 2022
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Geetha ManiamSchool of Postgraduate Studies, International Medical University, Bukit Jalil, Malaysia.
Chun-Wai MaiDepartment of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, Malaysia.
Mohd ZulkefeliDepartment of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, Malaysia.
Christine DufèsStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Doryn Meam-Yee TanProduct Development and Advisory Services Division, Malaysian Palm Oil Board, Bandar Baru Bangi, Malaysia.
Ju-Yen FuProduct Development and Advisory Services Division, Malaysian Palm Oil Board, Bandar Baru Bangi, Malaysia.
International Medical University · MYMalaysian Palm Oil Board · MYMonash University Malaysia · MYUniversity of Strathclyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plant-derived phytonutrients have emerged as health enhancers. Tocotrienols from the vitamin E family gained high attention in recent years due to their multi-targeted biological properties, including lipid-lowering, neuroprotection, anti-inflammatory, antioxidant, and anticancer effects. Despite well-defined mechanism of action as an anti-cancer agent, their clinical use is hampered by poor pharmacokinetic profile and low oral bioavailability. Delivery systems based on nanotechnology were proven to be advantageous in elevating the delivery of tocotrienols to tumor sites for enhanced efficacy. To date, preclinical development of nanocarriers for tocotrienols include niosomes, lipid nanoemulsions, nanostructured lipid carriers (NLCs) and polymeric nanoparticles. Active targeting was explored via the use of transferrin as targeting ligand in niosomes.

Indexed as

cancerdrug deliverynanoformulationnanotechnologytocotrienols

Identifiers

PMID30534071
PMCPMC6276840
OpenAlexW2902209340

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.